1. Loh HY, Norman BP, Lai KS, Rahman NMANA, Alitheen NBM, Osman MA. The regulatory role of microRNAs in breast cancer. Int J Mol Sci 2019;20:4940.
2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209–49.
3. Yip C, Pathy NB, Teo S. A review of breast cancer research in Malaysia. Med J Malaysia 2014;69:8–22.
4. Azizah A, Hashimah B, Nirmal K, Siti Zubaidah A, Puteri N, Nabihah A, et al. Malaysia National cancer registry report (MNCR). Putrajaya, Malaysia: National Cancer Institute, Ministry of Health; 2019.
5. Ellsworth RE, Blackburn HL, Shriver CD, Soon-Shiong P, Ellsworth DL. Molecular heterogeneity in breast cancer: State of the science and implications for patient care. Semin Cell Dev Biol 2017;64:65–72.
6. Yersal O, Barutca S. Biological subtypes of breast cancer: Prognostic and therapeutic implications. World J Clin Oncol 2014;5:412.
7. Kennecke H, Yerushalmi R, Woods R, Cheang MCU, Voduc D, Speers CH, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol 2010;28:3271–7.
8. Bhargava R, Beriwal S, Dabbs DJ, Ozbek U, Soran A, Johnson RR, et al. Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: A single institutional experience with 359 cases. Cancer 2010;116:1431–9.
9. Pathmanathan N, Balleine RL. Ki67 and proliferation in breast cancer. J Clin Pathol 2013;66:512–6.
10. Creighton CJ. The molecular profile of luminal B breast cancer. Biologics 2012;6:289.
11. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med 2010;363:1938–48.
12. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res 2007;13:4429–34.
13. Exman P, Tolaney SM. HER2-positive metastatic breast cancer: A comprehensive review. Clin Adv Hematol Oncol 2021;19:40–50.
14. Schnitt SJ. Classification and prognosis of invasive breast cancer: From morphology to molecular taxonomy. Mod Pathol 2010;23:S60–4.
15. Yan M, Parker BA, Schwab R, Kurzrock R. HER2 aberrations in cancer: Implications for therapy. Cancer Treat Rev 2014;40:770–80.
16. Goethals A, Rose J. Mastectomy. StatPearls Publishing. 2022.
17. Montemurro F, Nuzzolese I, Ponzone R. Neoadjuvant or adjuvant chemotherapy in early breast cancer? Expert Opin Pharmacother 2020;21:1071–82.
18. Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 2015;372:724–34.
19. Waks AG, Winer EP. Breast cancer treatment: A review. JAMA 2019;321:288–300.
20. Asselain B, Barlow W, Bartlett J, Bergh J, Bergsten-Nordström E, Bliss J, et al. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: Metaanalysis of individual patient data from ten randomised trials. Lancet Oncol 2018;19:27–39. 
21. Broët P, Scholl SM, de la Rochefordière A, Fourquet A, Moreau T, De Rycke Y, et al. Short and long‐term effects on survival in breast cancer patients treated by primary chemotherapy: An updated analysis of a randomized trial. Breast Cancer Res Treat 1999;58:151–6.
22. Chira C, Kirova YM, Liem X, Campana F, Peurien D, Amessis M, et al. Helical tomotherapy for inoperable breast cancer: A new promising tool. BioMed Res Int 2013;2013:264306.
23. Pilewskie M, Morrow M. Axillary nodal management following neoadjuvant chemotherapy: A review. JAMA Oncol 2017;3:549–55.
24. Van J, Hage C, Velde J, Tubiana-Hulin M, Vandervelden C. Preoperative chemotherapy in primary operable breast cancer: Results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 2001;22:4224–37.
25. Bindayi A, Hamilton ZA, McDonald ML, Yim K, Millard F, McKay RR, et al. Neoadjuvant therapy for localized and locally advanced renal cell carcinoma. Urol Oncol 2018;36:31– 37.
26. Reig B, Heacock L, Lewin A, Cho N, Moy L. Role of MRI to assess response to neoadjuvant therapy for breast cancer. J Magn Reson Imaging 2020;52:27145.
27. Catalanotto C, Cogoni C, Zardo G. MicroRNA in control of gene expression: An overview of nuclear functions. Int J Mol Sci 2016;17:1712.
28. Wang W, Luo YP. MicroRNAs in breast cancer: Oncogene and tumor suppressors with clinical potential. J Zhejiang Univ 2015;16:18–31.
29. Bartel DP. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004;116:281–97.
30. Fang H, Xie J, Zhang M, Zhao Z, Wan Y, Yao Y. miRNA-21 promotes proliferation and invasion of triple-negative breast cancer cells through targeting PTEN. Am J Transl Res 2017;9:953.
31. Thakur P, Saini RV, Chhillar AK, Saini NK, Thakur VK, Siwal SS, et al. Alteration in the expression of microRNA-21 regulated target genes: Role in breast cancer. Biocell 2022;46:309–24.
32. Zhang CM, Zhao J, Deng HY. MiR-155 promotes proliferation of human breast cancer MCF-7 cells through targeting tumor protein 53-induced nuclear protein 1. J Biomed Sci 2013;20:1–10.
33. Carbognin L, Miglietta F, Paris I, Dieci MV. Prognostic and predictive implications of PTEN in breast cancer: Unfulfilled promises but intriguing perspectives. Cancers 2019;11:1401.
34. Meric-Bernstam F, Chen H, Akcakanat A, Do KA, Lluch A, Hennessy BT, et al. Aberrations in translational regulation are associated with poor prognosis in hormone receptorpositive breast cancer. Breast Cancer Res 2012;14:1–11. 
35. Aksan H, Kundaktepe BP, Sayili U, Velidedeoglu M, Simsek G, Koksal S, et al. Circulating miR‐155, let‐7c, miR‐21, and PTEN levels in differential diagnosis and prognosis of idiopathic granulomatous mastitis and breast cancer. Biofactors 2020;46:955–62.
36. Alowiri NH, Hanafy SM, Haleem RA, Abdellatif A. PIK3CA and PTEN genes expressions in breast cancer. Asian Pac J Cancer Prev 2019;20:2841.
37. Cao Z, Yoon JH, Nam SW, Lee JY, Park WS. PDCD4 expression inversely correlated with miR-21 levels in gastric cancers. J Cancer Res Clin Oncol 2012;138:611–9.
38. Lin HC, Cheng YW, Hsu NY. The association of miR-21, HER2/neu, and PTEN expression and clinical outcome of breast cancer. Cancer Res 2014;74:1470.
39. Dong G, Liang X, Wang D, Gao H, Wang L, Wang L, et al. High expression of miR-21 in triple-negative breast cancers was correlated with a poor prognosis and promoted tumor cell in vitro proliferation. Med Oncol 2014;31:1–10. 
40. Ding Y, Wu W, Ma Z, Shao X, Zhang M, Wang Z. Potential value of MicroRNA-21 as a biomarker for predicting the prognosis of patients with breast cancer: A protocol for meta-analysis and bioinformatics analysis. Medicine 2021;100:e25964.
41. Hamam R, Hamam D, Alsaleh KA, Kassem M, Zaher W, Alfayez M, et al. Circulating microRNAs in breast cancer: Novel diagnostic and prognostic biomarkers. Cell Death Dis 2017;8:e3045.
42. Usmani A, Shoro AA, Memon Z, Hussain M, Rehman R. Diagnostic, prognostic and predictive value of MicroRNA-21 in breast cancer patients, their daughters and healthy individuals. Am J Cancer Res 2015;5:2484.
43. Jahagirdar D, Gore CR, Patel H, Maria K, Tandon I, Sharma NK. Induction of apoptotic death and cell cycle arrest in HeLa cells by extracellular factors of breast cancer cells. Asian Pac J Cancer Prev 2018;19:3307.
44. Wong PB, Wiley EO, Johnson WE, Ryder OA, O’Brien SJ, Haussler D, et al. Tissue sampling methods and standards for vertebrate genomics. GigaScience 2012;1:2047-217X-1- 8.
45. Rao X, Huang X, Zhou Z, Lin X. An improvement of the 2^ (–delta delta CT) method for quantitative real-time polymerase chain reaction data analysis. Biostat Bioinforma Biomath 2013;3:71.
46. Hug KA, Anthony L, Eldeiry D, Benson J, Wheeler E, Mousa S, et al. Expression and tissue distribution of MicroRNA-21 in malignant and benign breast tissues. Anticancer Res 2015;35:3175–83.
47. Ma L, Yang Y, Sun X, Jiang M, Ma Y, Yang X, et al. Propofol regulates the expression of TLR4 through miR 21 in human umbilical vein endothelial cells. Mol Med Rep 2017;16:9074– 80.
48. Kia V, Beigli MS, Hosseini V, Koochaki A, Paryan M, Mohammadi-Yeganeh S. Is miR-144 an effective inhibitor of PTEN mRNA: A controversy in breast cancer. In Vitro Cell Dev Biol Anim 2018;54:621–8.
49. Wang Y, Liu Z, Shen J. MicroRNA-421-targeted PDCD4 regulates breast cancer cell proliferation. Int J Mol Med 2019;43:267–75.
50. Arisan ED, Rencuzogullari O, Cieza-Borrella C, Miralles Arenas F, Dwek M, Lange S, et al. Mir-21 is required for the epithelial–mesenchymal transition in mda-mb-231 breast cancer cells. Int J Mol Sci 2021;22:1557.
51. Welsh J. Chapter 40 - Animal models for studying prevention and treatment of breast cancer. In Conn PM, editor. Animal Models for the Study of Human Disease. Cambridge: Academic Press; 2013.
52. Sangour MH, Ali IM, Atwan ZW, Al Ali AAALA. Effect of Ag nanoparticles on viability of MCF-7 and Vero cell lines and gene expression of apoptotic genes. Egypt J Med Hum Genet 2021;22:1–11.
53. Simorangkir D, Masfria M, Harahap U, Satria D. Activity anticancer n-hexane fraction of Cyperus rotundus L. rhizome to breast cancer MCF-7 cell line. Open Access Maced J Med Sci 2019;7:3904.
54. Liu ZQ, Mahmood T, Yang PC. Western blot: Technique, theory, and trouble shooting. North Am J Med Sci 2014;6:160. 
55. Zhang W, Hu C, Zhang C, Luo C, Zhong B, Yu X. MiRNA-132 regulates the development of osteoarthritis in correlation with the modulation of PTEN/PI3K/AKT signaling. BMC Geriatr 2021;21:1–10.
56. Ling T, Aminnur H, Ahmad N, Mahamad S, Baghawi A. A systematic approach in restructuring elective breast & endocrine cancer surgery during COVID-19 pandemic in Malaysia. Int J Surg Res Pract 2020;7:117.
57. Akoglu H. User's guide to correlation coefficients. Turk J Emerg Med 2018;18:91–3.
58. Schober P, Boer C, Schwarte LA. Correlation coefficients: Appropriate use and interpretation. Anesth Analg
2018;126:1763–8. 
59. Han JG, Jiang YD, Zhang CH, Yang YM, Pang D, Song YN, et al. A novel panel of serum miR-21/miR-155/miR-365 as a potential diagnostic biomarker for breast cancer. Ann Surg Treat Res 2017;92:55–66.
60. Najjary S, Mohammadzadeh R, Mokhtarzadeh A, Mohammadi A, Kojabad AB, Baradaran B. Role of miR-21 as an authentic oncogene in mediating drug resistance in breast cancer. Gene 2020;738:144453.
61. Petrović N. miR-21 might be involved in breast cancer promotion and invasion rather than in initial events of breast cancer development. Mol Diagn Ther 2016;20:97–110.
62. Wang G, Wang L, Sun S, Wu J, Wang Q. Quantitative measurement of serum microRNA-21 expression in relation to breast cancer metastasis in Chinese females. Ann Lab Med 2015;35:226.
63. Zhang C, Liu K, Li T, Fang J, Ding Y, Sun L, et al. miR-21: A gene of dual regulation in breast cancer. Int J Oncol 2016;48:161– 72.
64. Zhu M, Wang X, Gu Y, Wang F, Li L, Qiu X. MEG3 overexpression inhibits the tumorigenesis of breast cancer by downregulating miR-21 through the PI3K/Akt pathway. Arch Biochem Biophys 2019;661:22–30.
65. Kumarswamy R, Volkmann I, Thum T. Regulation and function of miRNA-21 in health and disease. RNA Biol
2011;8:706–13.
66. Peng Y, Croce CM. The role of MicroRNAs in human cancer. Signal Transduct Target Ther 2016;1:1–9.
67. Si W, Shen J, Zheng H, Fan W. The role and mechanisms of action of microRNAs in cancer drug resistance. Clin Epigenet 2019;11:1–24.
68. Fang M, Weng Z, Guan H, Sun Y. Expression of DJ-1, PTEN and AR in triple-negative breast cancer and its correlation with relative clinical parameters and prognosis. China J Cancer Prev Treat 2013;20:761–4.
69. Huang Y, Tan Y. The correlations between expression of Livin and PTEN and angiogenesis of breast cancer. Chin J Immunol 2012;28:886–9.
70. Li S, Shen Y, Wang M, Yang J, Lv M, Li P, et al. Loss of PTEN expression in breast cancer: Association with clinicopathological characteristics and prognosis. Oncotarget 2017;8:32043.
71. Li X, Wang Q, Fu L, Liu M, Yu X. Expression of PTEN, p53 and EGFR in the molecular subtypes of breast carcinoma and the correlation among them. J Cent South Univ Med Sci 2015;40:973–8.
72. Tang Y, Xie L, XF E. Clinical significance of PTEN, p53 and EGFR in breast cancer. Mod Oncol 2014;22:345–9.
73. Cai Q, Yang HS, Li YC, Zhu J. Dissecting the Roles of PDCD4 in Breast Cancer. Front Oncol 2022;12:855807.
74. Abdulhussain MM, Hasan NA, Hussain AG. Interrelation of the circulating and tissue MicroRNA-21 with tissue PDCD4 expression and the invasiveness of Iraqi female breast tumors. Indian J Clin Biochem 2019;34:26–38.
75. Tao L, Wu Y, Zhang S. MiR-21-5p enhances the progression and paclitaxel resistance in drug-resistant breast cancer cell lines by targeting PDCD4. Neoplasma 2019;66:746–55. 
76. Sukhija S, Purohit P, Pareek P, Garg PK, Vishnoi JR, Elhence PA, et al. Circulating MiRNA-21 levels in breast cancer patients before and after chemotherapy and its association with clinical improvement. Indian J Clin Biochem 2023;2023:s12291-023-01129-0.
77. Walter BA, Gómez-Macias G, Valera VA, Sobel M, Merino MJ. miR-21 expression in pregnancy-associated breast cancer: A possible marker of poor prognosis. J Cancer 2011;2:67.
78. Kechagioglou P, Papi RM, Provatopoulou X, Kalogera E, Papadimitriou E, Grigoropoulos P, et al. Tumor suppressor PTEN in breast cancer: Heterozygosity, mutations and protein expression. Anticancer Res 2014;34:1387–400.
79. Qi L, Bart J, Tan LP, Platteel I, Sluis Tvd, Huitema S, et al. Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma. BMC Cancer 2009;9:1– 8.
80. Leslie NR, Downes CP. PTEN function: How normal cells control it and tumour cells lose it. Biochem J 2004;382:1–11.
81. Leslie NR, Spinelli L, Tibarewal P, Zilidis G, Weerasinghe N, Lim JC, et al. Indirect mechanisms of carcinogenesis via downregulation of PTEN function. Adv Enzyme Regul 2010;50:112–8.
82. Okahara F, Ikawa H, Kanaho Y, Maehama T. Regulation of PTEN phosphorylation and stability by a tumor suppressor candidate protein. J Biol Chem 2004;279:45300–3.
83. Dillon LM, Miller TW. Therapeutic targeting of cancers with loss of PTEN function. Curr Drug Targets 2014;15:65–79.
84. Liang H, He S, Yang J, Jia X, Wang P, Chen X, et al. PTENα, a PTEN isoform translated through alternative initiation, regulates mitochondrial function and energy metabolism. Cell Metab 2014;19:836–48.
85. Liu A, Zhu Y, Chen W, Merlino G, Yu Y. PTEN dual lipid-and protein-phosphatase function in tumor progression. Cancers 2022;14:3666.
86. Venne AS, Kollipara L, Zahedi RP. The next level of complexity: Crosstalk of posttranslational modifications. Proteomics 2014;14:513–24.
87. Shen SM, Zhang C, Ge MK, Dong SS, Xia L, He P, et al. PTENα and PTENβ promote carcinogenesis through WDR5 and H3K4 trimethylation. Nat Cell Biol 2019;21:1436–48.
88. Frankel LB, Christoffersen NR, Jacobsen A, Lindow M, Krogh A, Lund AH. Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem 2008;283:1026–33.
89. Fay MM, Clegg JM, Uchida KA, Powers MA, Ullman KS. Enhanced arginine methylation of programmed cell death 4 protein during nutrient deprivation promotes tumor cell viability. J Biol Chem 2014;289:17541–52.
90. Kalinichenko SV, Kopantzev EP, Korobko EV, Palgova IV, Zavalishina LE, Bateva MV, et al. Pdcd4 protein and mRNA level alterations do not correlate in human lung tumors. Lung Cancer 2008;62:173–80.
91. Mahmood N, Hanif M, Ahmed A, Jamal Q, Mushtaq S, Khan A, et al. Circulating miR-21 as a prognostic and predictive biomarker in oral squamous cell carcinoma. Pak J Med Sci 2019;35:1408.
92. Cui S, Lou S, Guo W, Jian S, Wu Y, Liu X, et al. Prediction of miR-21-5p in promoting the development of lung adenocarcinoma via PDZD2 regulation. Med Sci Monit 2020;26:e923366–1.
93. Zhou X, Wang X, Huang Z, Wang J, Zhu W, Shu Y, et al. Prognostic value of miR-21 in various cancers: An updating meta-analysis. PLoS One 2014;9:e102413.
94. Amirfallah A, Knutsdottir H, Arason A, Hilmarsdottir B, Johannsson OT, Agnarsson BA, et al. Hsa-miR-21-3p associates with breast cancer patient survival and targets genes in tumor suppressive pathways. PLoS One 2021;16:e0260327. 
95. Xiaofei W. Expressions of miR-21 and miR-210 in breast cancer and their predictive values for prognosis. Iran J Public Health 2020;49:21.
96. Wang H, Tan Z, Hu H, Liu H, Wu T, Zheng C, et al. microRNA-21 promotes breast cancer proliferation and metastasis by targeting LZTFL1. BMC Cancer 2019;19:1–13.
97. Sales ACV, Gomes da Silva IIF, Leite MC, Coutinho LL, Reis RB, Castoldi A, et al. Mirna21 expression in the breast cancer tumor tissue is independent of neoadjuvant chemotherapy. Breast Cancer Targets Ther 2020;12:141–51.
98. Rodríguez-Martínez A, de Miguel-Pérez D, Ortega FG, García-Puche JL, Robles-Fernández I, Exposito J, et al. Exosomal miRNA profile as complementary tool in the diagnostic and prediction of treatment response in localized breast cancer under neoadjuvant chemotherapy. Breast Cancer Res 2019;21:1–9.
99. Kalinina TS, Kononchuk VV, Yakovleva AK, Alekseenok EY, Sidorov SV, Gulyaeva LF. Association between lymph node status and expression levels of androgen receptor, miR-185, miR-205, and miR-21 in breast cancer subtypes. Int J Breast Cancer 2020;2020:3259393.
100. Yan M, Liu Q. Differentiation therapy: A promising strategy for cancer treatment. Chin J Cancer 2016;35:1–3.
101. Poudel P, Nyamundanda G, Patil Y, Cheang MCU, Sadanandam A. Heterocellular gene signatures reveal luminal - a breast cancer heterogeneity and differential therapeutic responses. NPJ Breast Cancer 2019;5:21.
102. Loibl S, Gianni L. HER2-positive breast cancer. Lancet 2017;389:2415–29.
103. Al-Thoubaity FK. Molecular classification of breast cancer: A retrospective cohort study. Ann Med Surg Lond 2020;49:44–8.
104. Arun RP, Cahill HF, Marcato P. Breast cancer subtype-specific MiRNAs: Networks, impacts, and the potential for intervention. Biomedicines 2022;10:651. 
105. Van't Veer LJ, Dai H, Van De Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530–6.
106. Mao H, Cao Y, Zou Z, Xia J, Zhao J. An enzyme-powered microRNA discriminator for the subtype-specific diagnosis of breast cancer. Chem Sci 2023;14:2097–106.